In 2005, Becky Roth's dentist discovered a white spot on her tongue. It was benign, but five years later another spot led to the discovery of a tumor at the base of her tongue and jaw.
In a powerful speech to a packed house, Becky Roth spoke emotionally about the cancer that changed, but didn’t claim, her life. And, despite losing two leg bones used for her jaw reconstruction – and against all odds – she will run in the 2018 Providence Hood to Coast relay race to raise money for cancer research at Providence.
A recent assessment of the first 170 throat-cancer patients treated with transoral robotic surgery followed by risk-adapted adjuvant therapy at Providence Cancer Institute offers compelling evidence in favor of this new treatment approach.
Many clinical trials are open only to patients with metastatic disease. One of the translational research goals of the Providence Head and Neck Cancer Program is to bring immunotherapy into treatment earlier.
Adoptive T-cell transfer therapy is emerging as one of the most effective treatments to date for people with advanced melanoma. Now this treatment is available to patients with advanced or recurrent head and neck cancers through a clinical trial at Providence Cancer Institute.
Providence Oral, Head and Neck Cancer Clinic offers world-class care for patients with benign and malignant tumors of the oral cavity (mouth), tongue, pharynx (throat), larynx (voice box), nose, paranasal sinuses, salivary glands and thyroid gland, as well as tumors at the skull base. Our medical and surgical oncology teams work collaboratively to start patients on treatment regimens very quickly.
The complex procedure, known as a “Jaw in a Day,” has been performed in only a few highly specialized centers in the world. Smith’s procedure, performed in August at Providence St. Vincent Medical Center, was the first on the West Coast.
Amber Watters, DDS, a dental oncologist with Providence Oral, Head and Neck Cancer Program and Clinic, has opened a clinical study of a device that could lessen the effects of trismus, even in patients years or decades out from their diagnosis and treatment.
Researchers at Providence Cancer Center received a $75,000 grant to study biomarkers that may help predict responses to immuntherapy and assist oncologists in making treatment-related decisions for patients with head and neck cancers.
Providence Oral, Head and Neck Cancer Clinics now serve patients at two locations: Providence Portland Medical Center and a newly opened clinic at Providence St. Vincent Medical Center.